search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


A randomised controlled study with whole-cell or acellular pertussis vaccines in combination with regular DT-IPV vaccine and a new poliomyelitis (IPV-Vero) component in children 4 years of age in the Netherlands.


- candidate number3830
- NTR NumberNTR1406
- ISRCTNISRCTN wordt niet meer aangevraagd
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR14-aug-2008
- Secondary IDsLVO66A, LVO121A 
- Public TitleA randomised controlled study with whole-cell or acellular pertussis vaccines in combination with regular DT-IPV vaccine and a new poliomyelitis (IPV-Vero) component in children 4 years of age in the Netherlands.
- Scientific TitleA randomised controlled study with whole-cell or acellular pertussis vaccines in combination with regular DT-IPV vaccine and a new poliomyelitis (IPV-Vero) component in children 4 years of age in the Netherlands.
- ACRONYMApeldoorn studie
- hypothesisTo compare the immunogenicity of the Dutch whole cell vaccine versus 3 acellular pertussis vaccines administered as a booster at 4 years of age by measuring the antibody levels in serum after 1 month and 2 years.
- Healt Condition(s) or Problem(s) studiedInfectious diseases, Whooping cough, Bordetella pertussis
- Inclusion criteria1. Children in good general health eligible for the DT-IPV vaccination at 4 years of age
2. Written informed consent (IC) from parents
- Exclusion criteria1. Severe acute illness or fever (>38.5) within two days before vaccination
2. Present evidence of serious disease(s) demanding medical treatment that might interfere with the results of the study
3. Known or suspected allergy to any of the vaccine components
4. Known or suspected immune disorder
5. History of any neurological disorder, including epilepsy
6. Previous administration of plasma products (including immunoglobulins)
7. Previous vaccination with any other vaccine than those used in the National Immunisation Programme.
- mec approval receivedyes
- multicenter trialyes
- randomisedyes
- masking/blindingNone
- controlActive
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-mrt-1998
- planned closingdate1-sep-2000
- Target number of participants180
- InterventionsA total of 180 children 4 years of age were divided over 5 groups.
1. DT-IPV vaccine administration as controlgroup (N=45)
2. DTwP-IPV (N=44)
3. DT-IPV and aP from SKB (N=44)
4. DT-IPV and aP from Wyeth-Lederle (N=23)
5 DT-IPV and aP from Pasteur-Merieux (N=24).
Blood samples were taken just before the vaccination, 4-6 weeks and 2 years postvaccination.
- Primary outcomeTo compare the immunogenicity of the whole cell versus the acellular pertussis vaccine components as measured by the antibody titers at the 3 time points. The antibody levels are determined by a twofold serial dilution ELISA.
- Secondary outcomeThe occurrence of adverse events after the administration of the different pertussis vaccines as recorded by the parents (non-blinded). Antibody titers directed against all other vaccine components are measured.
- TimepointsBlood samples were taken just before the vaccination, 4-6 weeks and 2 years postvaccination.
- Trial web siteN/A
- statusstopped: trial finished
- CONTACT FOR PUBLIC QUERIESPhD G. Berbers
- CONTACT for SCIENTIFIC QUERIESPhD G. Berbers
- Sponsor/Initiator National Institute for Public Health and the Environment (RIVM)
- Funding
(Source(s) of Monetary or Material Support)
The Netherlands Healthcare Inspectorate
- PublicationsGAM Berbers et al. RIVM report 105000 001, Jan. 1999
- Brief summaryIn this study the immunogenicity of the whole cell pertussis vaccine and 3 acellular pertussis vaccines is compared after administration as a booster in children 4 years of age. The occurence of adverse events within 1 week after vaccination and the persistence of antibody levels after 2 years are also investigated.
After vaccination with the ACV’s almost all the titers are high against the different pertussis components and generally reflect the composition of these components present in the vaccines. The titers are comparable with those observed in other trials with these vaccines. After vaccination with the WCV the antibody levels are lower as found for the ACV's and more diverse, varying from good to low for the different pertussis vaccine antigens. A drawback of the WCV is the rate of adverse events which is in general 4 times as much as observed for the ACV's, although the adverse reactions are mostly mild and of limited duration. 2 Years after the booster vaccination almost all pertussis antibody titers have decreased to background level.
- Main changes (audit trail)
- RECORD14-aug-2008 - 22-aug-2008


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl